410,699 Shares in West Pharmaceutical Services, Inc. $WST Purchased by Deutsche Bank AG

Deutsche Bank AG acquired a new stake in West Pharmaceutical Services, Inc. (NYSE:WST) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor acquired 410,699 shares of the medical instruments supplier’s stock, valued at approximately $147,441,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Perigon Wealth Management LLC purchased a new position in shares of West Pharmaceutical Services during the 2nd quarter valued at approximately $671,000. Trust Co. of Vermont purchased a new stake in West Pharmaceutical Services in the 2nd quarter worth $72,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in West Pharmaceutical Services in the 2nd quarter worth $67,575,000. Plato Investment Management Ltd acquired a new position in West Pharmaceutical Services during the second quarter worth $900,000. Finally, Simplicity Wealth LLC acquired a new position in West Pharmaceutical Services during the second quarter worth $421,000. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

West Pharmaceutical Services Trading Up 1.7%

Shares of WST stock opened at $352.32 on Thursday. West Pharmaceutical Services, Inc. has a fifty-two week low of $223.83 and a fifty-two week high of $386.00. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.12 and a current ratio of 2.82. The stock’s fifty day moving average is $347.64 and its two-hundred day moving average is $298.51. The firm has a market capitalization of $24.80 billion, a P/E ratio of 45.11, a PEG ratio of 2.42 and a beta of 1.15.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.08 by $0.29. The business had revenue of $872.30 million during the quarter, compared to analyst estimates of $839.98 million. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The company’s revenue for the quarter was up 13.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.84 earnings per share. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Research analysts expect that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were issued a $0.22 dividend. The ex-dividend date was Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a yield of 0.2%. West Pharmaceutical Services’s dividend payout ratio is presently 11.27%.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. KeyCorp increased their price objective on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a report on Thursday, July 2nd. TD Cowen reissued a “buy” rating on shares of West Pharmaceutical Services in a research note on Wednesday, July 15th. Evercore restated an “outperform” rating and set a $425.00 price target on shares of West Pharmaceutical Services in a research report on Monday, July 27th. Stephens reiterated an “overweight” rating and issued a $360.00 price objective on shares of West Pharmaceutical Services in a report on Tuesday, June 2nd. Finally, Weiss Ratings upgraded West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, West Pharmaceutical Services has a consensus rating of “Moderate Buy” and an average price target of $368.08.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.